
A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with …
May 29, 2024 · WTX-124 is a half-life extended, masked cytokine (INDUKINE molecule) rationally engineered to release wild type IL-2 in tumors. We previously reported that WTX-124 is clinically active as a monotherapy at doses safely administered in the outpatient setting.
Discovery of a Conditionally Activated IL-2 that Promotes
May 3, 2022 · Here, we describe the design and characterization of a conditionally activated IL-2 prodrug, WTX-124, that takes advantage of the dysregulated protease milieu of tumors.
• Our work shows that WTX-124, a pro-drug containing wild-type IL-2, is selectively processed and activated in tumors and is efficacious in murine models, even in the presence of regulatory T cells • WTX-124 activity is dependent on the processing of the pro-drug as a non-cleavable version of WTX-124 (WTX-124-NC) is not efficacious in our ...
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 ...
4 days ago · WTX-124: a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule being developed as monotherapy and in combination with pembrolizumab in multiple solid tumor types. Werewolf continues to evaluate WTX-124 as a monotherapy and in combination with pembrolizumab through the ongoing Phase 1/1b clinical trial ...
Werewolf Therapeutics Presents Preliminary Monotherapy Data …
Nov 3, 2023 · Study WTX-124x2101 is evaluating WTX-124 as a monotherapy and in combination with pembrolizumab in patients with immunotherapy sensitive advanced or metastatic solid tumors who have failed standard of care treatment, including checkpoint inhibitor therapy.
Werewolf Therapeutics Updates on Clinical Trials for WTX-124
4 days ago · Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a ...
Discovery of a Conditionally Activated IL-2 that Promotes …
May 3, 2022 · WTX-124, an IL-2 containing INDUKINE protein, was designed to enhance the clinical profile of rhIL-2 treatment by facilitating less frequent systemic delivery, increasing the tumor exposure of the molecule, and decreasing the toxicity associated with high-dose IL-2.
737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 ...
WTX-124 exhibits approximately dose-proportional PK with very low levels of active IL-2 (<1% of prodrug). Tumor biopsies are being analyzed for changes in the frequency and functionality of tumor-infiltrating lymphocytes, PD-L1 expression, and immune cell gene expression.
Abstract 2054: WTX-124 is a novel IL-2 pro-drug that is …
Jun 15, 2022 · To address these limitations, we designed WTX-124, an IL-2 pro-drug (IL-2 INDUKINE™ protein) that takes advantage of dysregulated protease activity in the tumor microenvironment (TME) to selectively release active IL-2 in …
WTX-124 by Werewolf Therapeutics for Adenocarcinoma Of The ...
The company investigating WTX-124, a conditionally activated interleukin-2 (IL-2) based drug to treat multiple tumor types and WTX-330 and WTX-613 drugs administered as monotherapies for refractory and immunologically unresponsive tumors.